AR111494A1 - Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer - Google Patents

Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer

Info

Publication number
AR111494A1
AR111494A1 ARP180101102A ARP180101102A AR111494A1 AR 111494 A1 AR111494 A1 AR 111494A1 AR P180101102 A ARP180101102 A AR P180101102A AR P180101102 A ARP180101102 A AR P180101102A AR 111494 A1 AR111494 A1 AR 111494A1
Authority
AR
Argentina
Prior art keywords
hydrogen
anilinoquinazoline
compounds
cancer treatment
alkoxy
Prior art date
Application number
ARP180101102A
Other languages
English (en)
Inventor
Tudor Grecu
James Michael Smith
Stuart Eric Pearson
Martin John Packer
Jason Grant Kettle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR111494A1 publication Critical patent/AR111494A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

El proceso para su preparación; las composiciones farmacéuticas que los contienen y su uso en el tratamiento de las enfermedades mediadas por KIT. Reivindicación 1: Un compuesto de la fórmula (1), o una sal del mismo aceptable desde el punto de vista farmacéutico, caracterizado porque: R¹ se selecciona de hidrógeno y flúor; R² se selecciona de flúor y alcoxi C₁₋₂; R³ se selecciona de hidrógeno y metoxi; y R⁴ es un alquilo C₁₋₃, opcionalmente sustituido con un grupo seleccionado de alcoxi C₁₋₃ y NR⁵R⁶, en donde R⁵ y R⁶ son cada uno independientemente hidrógeno o metilo; o un anillo de heterociclilo de 4 a 6 elementos que contiene un átomo de oxígeno.
ARP180101102A 2017-04-27 2018-04-27 Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer AR111494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762490859P 2017-04-27 2017-04-27

Publications (1)

Publication Number Publication Date
AR111494A1 true AR111494A1 (es) 2019-07-17

Family

ID=62091877

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101102A AR111494A1 (es) 2017-04-27 2018-04-27 Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer

Country Status (14)

Country Link
US (2) US10273227B2 (es)
EP (1) EP3615522B1 (es)
JP (1) JP7128204B2 (es)
KR (1) KR102603153B1 (es)
CN (1) CN110573505B (es)
AR (1) AR111494A1 (es)
AU (1) AU2018259078B2 (es)
BR (1) BR112019022229A2 (es)
CA (1) CA3059283A1 (es)
ES (1) ES2888298T3 (es)
MX (1) MX2019012847A (es)
RU (1) RU2769694C2 (es)
TW (1) TWI774758B (es)
WO (1) WO2018197642A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012847A (es) * 2017-04-27 2022-01-07 Astrazeneca Ab Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
EP4210743A1 (en) 2020-09-10 2023-07-19 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
AU2021339954A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
JP2023542291A (ja) 2020-09-10 2023-10-06 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
TW202345831A (zh) * 2021-12-09 2023-12-01 美商迪賽孚爾製藥有限公司 Ｋｉｔ激酶抑制劑及其使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JP4870304B2 (ja) 1999-09-21 2012-02-08 アストラゼネカ アクチボラグ キナゾリン誘導体およびそれらの医薬品としての使用
DE60208364T2 (de) 2001-04-27 2006-09-28 Kirin Beer K.K. Chinolinderivate mit einer azolylgruppe und chinazolinderivate
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
US20050171172A1 (en) * 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20070106549A1 (en) 2005-11-04 2007-05-10 Stocking Christine A Turnkey aviation budget management
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
US20110104161A1 (en) 2008-05-14 2011-05-05 Burgess Teresa L Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102532042A (zh) * 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
CN102918029B (zh) * 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN103254142B (zh) 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104130200B (zh) 2014-07-01 2016-04-20 中山大学 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用
MX2019012847A (es) * 2017-04-27 2022-01-07 Astrazeneca Ab Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
US11053223B2 (en) 2017-04-27 2021-07-06 Astrazeneca Ab Phenoxyquinazoline compounds and their use in treating cancer

Also Published As

Publication number Publication date
RU2019136279A (ru) 2021-05-27
US20190263787A1 (en) 2019-08-29
US10829479B2 (en) 2020-11-10
KR20190141203A (ko) 2019-12-23
CN110573505A (zh) 2019-12-13
AU2018259078B2 (en) 2021-10-07
ES2888298T3 (es) 2022-01-03
US10273227B2 (en) 2019-04-30
AU2018259078A1 (en) 2019-10-17
RU2019136279A3 (es) 2021-05-31
US20180312490A1 (en) 2018-11-01
MX2019012847A (es) 2022-01-07
EP3615522A1 (en) 2020-03-04
CA3059283A1 (en) 2018-11-01
TW201904960A (zh) 2019-02-01
KR102603153B1 (ko) 2023-11-15
JP7128204B2 (ja) 2022-08-30
JP2020517677A (ja) 2020-06-18
TWI774758B (zh) 2022-08-21
CN110573505B (zh) 2023-04-11
BR112019022229A2 (pt) 2020-05-12
WO2018197642A1 (en) 2018-11-01
EP3615522B1 (en) 2021-08-04
RU2769694C2 (ru) 2022-04-05

Similar Documents

Publication Publication Date Title
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
AR106053A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR100340A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR110088A1 (es) Inhibidores de magl
AR097325A1 (es) Pirroles anillados
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR094553A1 (es) Formas de oxadiazolpirazina
AR093937A1 (es) Compuestos quimicos
AR104880A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR101479A1 (es) Derivados de 6-alquinil-piridina